185 related articles for article (PubMed ID: 11740817)
1. Thalidomide: a novel template for anticancer drugs.
Stirling D
Semin Oncol; 2001 Dec; 28(6):602-6. PubMed ID: 11740817
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.
Marriott JB; Dredge K; Dalgleish AG
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Sep; 3(3):181-6. PubMed ID: 12871024
[TBL] [Abstract][Full Text] [Related]
3. Properties of thalidomide and its analogues: implications for anticancer therapy.
Teo SK
AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide analogs as emerging anti-cancer drugs.
Dredge K; Dalgleish AG; Marriott JB
Anticancer Drugs; 2003 Jun; 14(5):331-5. PubMed ID: 12782937
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.
Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PP; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI
J Pharmacol Exp Ther; 2003 Jun; 305(3):1222-32. PubMed ID: 12649301
[TBL] [Abstract][Full Text] [Related]
6. Immunological effects of thalidomide and its chemical and functional analogs.
Dredge K; Marriott JB; Dalgleish AG
Crit Rev Immunol; 2002; 22(5-6):425-37. PubMed ID: 12803319
[TBL] [Abstract][Full Text] [Related]
7. IMiDs: a novel class of immunomodulators.
Knight R
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide - current understanding of mechanistic properties.
Tageja N
Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide: an old drug with new clinical applications.
Laffitte E; Revuz J
Expert Opin Drug Saf; 2004 Jan; 3(1):47-56. PubMed ID: 14680461
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
Ladizinski B; Shannon EJ; Sanchez MR; Levis WR
J Drugs Dermatol; 2010 Jul; 9(7):814-26. PubMed ID: 20677538
[TBL] [Abstract][Full Text] [Related]
12. A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders.
Kopp KO; Greer ME; Glotfelty EJ; Hsueh SC; Tweedie D; Kim DS; Reale M; Vargesson N; Greig NH
Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238617
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide treatment in multiple myeloma.
Strasser K; Ludwig H
Blood Rev; 2002 Dec; 16(4):207-15. PubMed ID: 12350364
[TBL] [Abstract][Full Text] [Related]
14. [Thalidomide: mechanisms of action and new insights in hematology].
Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide: emerging role in cancer medicine.
Richardson P; Hideshima T; Anderson K
Annu Rev Med; 2002; 53():629-57. PubMed ID: 11818493
[TBL] [Abstract][Full Text] [Related]
16. [The revival of thalidomide: an old drug with new indications].
Laffitte E
Rev Prat; 2006 Nov; 56(18):1977-83. PubMed ID: 17274497
[TBL] [Abstract][Full Text] [Related]
17. Recent advances of IMiDs in cancer therapy.
Li S; Gill N; Lentzsch S
Curr Opin Oncol; 2010 Nov; 22(6):579-85. PubMed ID: 20689431
[TBL] [Abstract][Full Text] [Related]
18. Potential new therapeutics for Waldenstrom's macroglobulinemia.
Zeldis JB; Schafer PH; Bennett BL; Mercurio F; Stirling DI
Semin Oncol; 2003 Apr; 30(2):275-81. PubMed ID: 12720152
[TBL] [Abstract][Full Text] [Related]
19. The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Bartlett JB; Dredge K; Dalgleish AG
Nat Rev Cancer; 2004 Apr; 4(4):314-22. PubMed ID: 15057291
[No Abstract] [Full Text] [Related]
20. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.
D'Amato RJ; Lentzsch S; Anderson KC; Rogers MS
Semin Oncol; 2001 Dec; 28(6):597-601. PubMed ID: 11740816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
